Compare Royalty Pharma plc Class A Ordinary Shares (RPRX) vs Vanguard Dividend Appreciation Index Fund ETF (VIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royalty Pharma plc Class A Ordinary Shares vs Vanguard Dividend Appreciation Index Fund ETF — how do they compare? Royalty Pharma plc Class A Ordinary Shares trades at $56.2 (market cap $25.27B), while Vanguard Dividend Appreciation Index Fund ETF trades at $237.41 (market cap $132.40B). The key difference: Vanguard Dividend Appreciation Index Fund ETF is far larger — about 5.2× Royalty Pharma plc Class A Ordinary Shares's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Vanguard Dividend Appreciation Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Royalty Pharma plc Class A Ordinary Shares for 0 Days and Vanguard Dividend Appreciation Index Fund ETF for 133 Days on average.
| RPRX | VIG | |
|---|---|---|
Market Cap | $25.27B | $132.40B |
Volume | 3,671,183 | 1,733,469 |
Sector | Health | — |
52-Week High | $63.96 | $246.61 |
52-Week Low | $35.44 | $210.70 |
Typical Hold Time | 0 Days | 133 Days |
Enterprise Value | $32.50B | — |
Dividend Yield | 1.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
VIG trades at $236.99, down 0.32% on the day, with technical indicators showing a bullish trend supported by moving averages. The ETF focuses on dividend growth companies with at least 10 consecutive years of dividend increases, offering a lower yield but stronger growth profile compared to peers. Recent news highlights VIG's 7.5% quarterly dividend increase and its strategic positioning for long-term income investors.
VIG presents a compelling option for investors seeking dividend growth with moderate risk, though its low current yield may not suit income-focused portfolios. Key risks include market volatility and the ETF's exclusion of high-yield dividend payers. Analyst sentiment remains positive given its historical 10% annual returns and quality screening criteria.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →About Vanguard Dividend Appreciation Index Fund ETF
The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that have a record of increasing dividends over time. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VIG →
